CD93 and neoplasm: In this study, Hu-PBMC mice bearing orthotopic pancreatic tumors were used to evaluate the therapeutic efficacy of our allogeneic DC treatment platform utilizing a lentiviral vector carrying CD93, CD40L, and CXCL13 with tumor-specific antigen pulsing.